Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
Sponsor: Shionogi
Summary
The primary objective of this study is to assess the safety and tolerability of BPN14770 in participants aged 9 to 45 years with JS.
Official title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Study of Zatolmilast (BPN14770) in Subjects With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome)
Key Details
Gender
All
Age Range
9 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-05-13
Completion Date
2030-01-31
Last Updated
2026-01-20
Healthy Volunteers
No
Interventions
BPN14770
Capsules for oral administration
Placebo
Capsules for oral administration
Locations (3)
Rush University Medical Center
Chicago, Illinois, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Seattle Children's Hospital
Seattle, Washington, United States